Literature DB >> 9437614

A structured instrument for estimating the economic cost of drug abuse treatment. The Drug Abuse Treatment Cost Analysis Program (DATCAP).

M T French1, L J Dunlap, G A Zarkin, K A McGeary, A T McLellan.   

Abstract

Drug abuse treatment programs need to know the cost of the services they provide. Indeed, continued public and private funding is now being linked to cost and performance measures, and programs can use financial data to improve organizational efficiency. However, one of the dangers of promoting cost studies at treatment programs is that most program staff are not technically prepared to perform a cost analysis and little user-friendly information is available to offer assistance. Furthermore, not all cost methods are consistent, which can lead to noncomparable estimates that are difficult to use for policy or planning purposes. Our paper tries to fill this gap in the research literature and provide treatment programs with a much-needed technical assistance tool. Specifically, we present a structured and scientifically-based instrument for estimating the economic cost of treatment services. The Drug Abuse Treatment Cost Analysis Program (DATCAP) is described in detail along with a companion instrument to analyze treatment financing; the Drug Abuse Treatment Financing Analysis Program (DATFin). The components of both instruments are outlined and findings from a variety of actual case studies are presented. Lastly, we discuss the DATCAP User's Manual, which will enable individual programs to begin collecting the necessary data and estimating economic costs at their own clinics.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9437614     DOI: 10.1016/s0740-5472(97)00132-3

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  55 in total

Review 1.  The cost-effectiveness of substance abuse treatment.

Authors:  P G Barnett
Journal:  Curr Psychiatry Rep       Date:  1999-12       Impact factor: 5.285

Review 2.  Family-based therapy for adolescent drug abuse: knowns and unknowns.

Authors:  T J Ozechowski; H A Liddle
Journal:  Clin Child Fam Psychol Rev       Date:  2000-12

3.  HIV transmission and the cost-effectiveness of methadone maintenance.

Authors:  G S Zaric; P G Barnett; M L Brandeau
Journal:  Am J Public Health       Date:  2000-07       Impact factor: 9.308

4.  Benefit-cost analysis of addiction treatment: methodological guidelines and empirical application using the DATCAP and ASI.

Authors:  Michael T French; Helena J Salomé; Jody L Sindelar; A Thomas McLellan
Journal:  Health Serv Res       Date:  2002-04       Impact factor: 3.402

Review 5.  Conducting economic evaluations of screening and brief intervention for hazardous drinking: Methods and evidence to date for informing policy.

Authors:  Alexander J Cowell; Jeremy W Bray; Michael J Mills; Jesse M Hinde
Journal:  Drug Alcohol Rev       Date:  2010-11

6.  Individual and system influences on waiting time for substance abuse treatment.

Authors:  Carey J A Carr; Jiangmin Xu; Cristina Redko; D Timothy Lane; Richard C Rapp; John Goris; Robert G Carlson
Journal:  J Subst Abuse Treat       Date:  2007-05-23

7.  Cost-effectiveness analysis of four interventions for adolescents with a substance use disorder.

Authors:  Michael T French; Silvana K Zavala; Kathryn E McCollister; Holly B Waldron; Charles W Turner; Timothy J Ozechowski
Journal:  J Subst Abuse Treat       Date:  2007-06-28

8.  Economic cost of the therapeutic workplace intervention added to methadone maintenance.

Authors:  Todd W Knealing; M Christopher Roebuck; Conrad J Wong; Kenneth Silverman
Journal:  J Subst Abuse Treat       Date:  2007-07-05

9.  Social costs of robbery and the cost-effectiveness of substance abuse treatment.

Authors:  Anirban Basu; A David Paltiel; Harold A Pollack
Journal:  Health Econ       Date:  2008-08       Impact factor: 3.046

10.  Patient and program costs, and outcomes, of including gender-sensitive services in intensive inpatient programs for substance use.

Authors:  Sarah E Hornack; Brian T Yates
Journal:  Eval Program Plann       Date:  2017-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.